Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

53 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Adjuvant low-dose interferon {alpha}2a with or without dacarbazine compared with surgery alone: a prospective-randomized phase III DeCOG trial in melanoma patients with regional lymph node metastasis.
Garbe C, Radny P, Linse R, Dummer R, Gutzmer R, Ulrich J, Stadler R, Weichenthal M, Eigentler T, Ellwanger U, Hauschild A. Garbe C, et al. Among authors: linse r. Ann Oncol. 2008 Jun;19(6):1195-201. doi: 10.1093/annonc/mdn001. Epub 2008 Feb 14. Ann Oncol. 2008. PMID: 18281266 Free article. Clinical Trial.
Adjuvant treatment with vindesine in comparison to observation alone in patients with metastasized melanoma after complete metastasectomy: a randomized multicenter trial of the German Dermatologic Cooperative Oncology Group.
Eigentler TK, Radny P, Hauschild A, Gutzmer R, Linse R, Pföhler C, Wagner SN, Schadendorf D, Ellwanger U, Garbe C; German Dermatologic Cooperative Oncology Group. Eigentler TK, et al. Among authors: linse r. Melanoma Res. 2008 Oct;18(5):353-8. doi: 10.1097/CMR.0b013e32830e3936. Melanoma Res. 2008. PMID: 18781134 Clinical Trial.
Prospective randomized multicenter adjuvant dermatologic cooperative oncology group trial of low-dose interferon alfa-2b with or without a modified high-dose interferon alfa-2b induction phase in patients with lymph node-negative melanoma.
Hauschild A, Weichenthal M, Rass K, Linse R, Ulrich J, Stadler R, Volkenandt M, Grabbe S, Proske U, Schadendorf D, Brockmeyer N, Vogt T, Rompel R, Kaufmann R, Kaatz M, Näher H, Mohr P, Eigentler T, Livingstone E, Garbe C. Hauschild A, et al. Among authors: linse r. J Clin Oncol. 2009 Jul 20;27(21):3496-502. doi: 10.1200/JCO.2008.21.3892. Epub 2009 May 11. J Clin Oncol. 2009. PMID: 19433681 Clinical Trial.
Efficacy of low-dose interferon {alpha}2a 18 versus 60 months of treatment in patients with primary melanoma of >= 1.5 mm tumor thickness: results of a randomized phase III DeCOG trial.
Hauschild A, Weichenthal M, Rass K, Linse R, Berking C, Böttjer J, Vogt T, Spieth K, Eigentler T, Brockmeyer NH, Stein A, Näher H, Schadendorf D, Mohr P, Kaatz M, Tronnier M, Hein R, Schuler G, Egberts F, Garbe C. Hauschild A, et al. Among authors: linse r. J Clin Oncol. 2010 Feb 10;28(5):841-6. doi: 10.1200/JCO.2009.23.1704. Epub 2010 Jan 4. J Clin Oncol. 2010. PMID: 20048184 Clinical Trial.
Dacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG).
Hauschild A, Garbe C, Stolz W, Ellwanger U, Seiter S, Dummer R, Ugurel S, Sebastian G, Nashan D, Linse R, Achtelik W, Mohr P, Kaufmann R, Fey M, Ulrich J, Tilgen W. Hauschild A, et al. Among authors: linse r. Br J Cancer. 2001 Apr 20;84(8):1036-42. doi: 10.1054/bjoc.2001.1731. Br J Cancer. 2001. PMID: 11308250 Free PMC article. Clinical Trial.
Temozolomide in combination with interferon-alfa versus temozolomide alone in patients with advanced metastatic melanoma: a randomized, phase III, multicenter study from the Dermatologic Cooperative Oncology Group.
Kaufmann R, Spieth K, Leiter U, Mauch C, von den Driesch P, Vogt T, Linse R, Tilgen W, Schadendorf D, Becker JC, Sebastian G, Krengel S, Kretschmer L, Garbe C, Dummer R; Dermatologic Cooperative Oncology Group. Kaufmann R, et al. Among authors: linse r. J Clin Oncol. 2005 Dec 10;23(35):9001-7. doi: 10.1200/JCO.2005.01.1551. Epub 2005 Oct 31. J Clin Oncol. 2005. PMID: 16260697 Clinical Trial.
Long-term survival benefit after adjuvant treatment of cutaneous melanoma with dacarbazine and low dose natural interferon alpha: A controlled, randomised multicentre trial.
Stadler R, Luger T, Bieber T, Köhler U, Linse R, Technau K, Schubert R, Schroth K, Vakilzadeh F, Volkenandt M, Gollnick H, Von Eick H, Thoren F, Strannegård O. Stadler R, et al. Among authors: linse r. Acta Oncol. 2006;45(4):389-99. doi: 10.1080/02841860600630954. Acta Oncol. 2006. PMID: 16760174 Clinical Trial.
Depressive mood changes and psychiatric symptoms during 12-month low-dose interferon-alpha treatment in patients with malignant melanoma: results from the multicenter DeCOG trial.
Heinze S, Egberts F, Rötzer S, Volkenandt M, Tilgen W, Linse R, Boettjer J, Vogt T, Spieth K, Eigentler T, Brockmeyer NH, Hinzpeter A, Hauschild A, Schaefer M. Heinze S, et al. Among authors: linse r. J Immunother. 2010 Jan;33(1):106-14. doi: 10.1097/CJI.0b013e3181b8bdb9. J Immunother. 2010. PMID: 19952950 Clinical Trial.
Health-related quality of life before and during adjuvant interferon-α treatment for patients with malignant melanoma (DeCOG-trial).
Ziefle S, Egberts F, Heinze S, Volkenandt M, Schmid-Wendtner M, Tilgen W, Linse R, Boettjer J, Vogt T, Spieth K, Eigentler T, Brockmeyer NH, Heinz A, Hauschild A, Schaefer M. Ziefle S, et al. Among authors: linse r. J Immunother. 2011 May;34(4):403-8. doi: 10.1097/CJI.0b013e31821b7a4b. J Immunother. 2011. PMID: 21499123 Clinical Trial.
53 results